A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics. 2017. CA. 2017;67(1):7–10. doi:10.3322/caac.21387.
   Google Scholar
• Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014;15(13):1521–1532. doi:10.1016/S1470-2045(14)71021-6.
   PubMed Web of Science ®Google Scholar
• Shao N, Wang Y, Jiang WY, Qiao D, Zhang SG, Wu Y, Zhang XX, Wang JL, Ding Y, Feng NH, et al. Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer. Int J Cancer. 2013;133(7):1743–1750. doi:10.1002/ijc.28162.
   PubMed Web of Science ®Google Scholar
• Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol. 2013;10(1):38–48. doi:10.1038/nrurol.2012.225.
   PubMed Web of Science ®Google Scholar
• Yin Y, Zhang Q, Zhang H, He Y, Huang J. Molecular signature to risk-stratify prostate cancer of intermediate risk. Clin Cancer Res. 2017;23(1):6–8. doi:10.1158/1078-0432.CCR-16-2400.
   PubMed Web of Science ®Google Scholar
• Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 2016;13(12):e1002194. doi:10.1371/journal.pmed.1002194.
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, Du Plessis M, Wang NQ, Davicioni E, et al. Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer. Eur Urol. 2019;76(1). doi:10.1016/j.eururo.2019.01.011
   Web of Science ®Google Scholar
• Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018;128(11):5185. doi:10.1172/JCI125184.
   PubMed Web of Science ®Google Scholar
• Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin oncol. 2011;29(17):2391–2396. doi:10.1200/JCO.2010.32.6421.
   PubMed Web of Science ®Google Scholar
• Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, et al. Prognostic utility of a new mrna expression signature of gleason score. Clin Cancer Res. 2017;23(1):81–87. doi:10.1158/1078-0432.CCR-16-1245.
   PubMed Web of Science ®Google Scholar
• Ong CW, Maxwell P, Alvi MA, McQuaid S, Waugh D, Mills I, Salto-Tellez M. A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. The Journal of Pathology: Clinical Research. 2018;4(2):103–113. doi:10.1002/cjp2.94.
   PubMedGoogle Scholar
• Kalina JL, Neilson DS, Lin YY, Hamilton PT, Comber AP, Loy EMH, Sahinalp SC, Collins CC, Hach F, Lum JJ, et al. mutational analysis of gene fusions predicts novel MHC class I-restricted T-cell epitopes and immune signatures in a subset of prostate cancer. Clin Cancer Res. 2017;23(24):7596–7607. doi:10.1158/1078-0432.CCR-17-0618.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi:10.1056/NEJMoa1207506.
   PubMed Web of Science ®Google Scholar
• Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, et al. Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score. BJU Int. 2014;113(3):399–407. doi:10.1111/bju.12424.
   PubMed Web of Science ®Google Scholar
• Intasqui P, Bertolla RP, Sadi MV. Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics. 2018;15(1):65–79. doi:10.1080/14789450.2018.1417846.
   PubMed Web of Science ®Google Scholar
• Kruck S, Bedke J, Kuczyk MA, Merseburger AS. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther. 2012;12(6):777–785. doi:10.1586/era.12.43.
   PubMed Web of Science ®Google Scholar
• van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol. 2014;65(6):1023–1031. doi:10.1016/j.eururo.2014.01.027.
   PubMed Web of Science ®Google Scholar
• Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ. Adverse disease features in gleason score 3 + 4 “favorable intermediate-risk” prostate cancer: implications for active surveillance. Eur Urol. 2017;72(3):442–447. doi:10.1016/j.eururo.2016.08.043.
   PubMed Web of Science ®Google Scholar
• Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, et al. Pathologic outcomes of gleason 6 favorable intermediate-risk prostate cancer treated with radical prostatectomy: implications for active surveillance. Clin Genitourin Cancer. 2018;16(3):226–234. doi:10.1016/j.clgc.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. J Cancer Res Clin Oncol. 2018;144(5):883–891. doi:10.1007/s00432-018-2615-7.
   PubMed Web of Science ®Google Scholar
• Ye J, Chu C, Chen M, Shi Z, Gan S, Qu F, Pan X, Yang Q, Tian Y, Wang L, et al. TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways. Oncol Rep. 2019;41(2):1169–1179. doi:10.3892/or.2018.6854.
   PubMed Web of Science ®Google Scholar
• Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, et al. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015;21(13):3061–3070. doi:10.1158/1078-0432.CCR-14-3334.
   PubMed Web of Science ®Google Scholar
• Visconti R, Grieco D. Fighting tubulin-targeting anticancer drug toxicity and resistance. Endocr Relat Cancer. 2017;24(9):T107–T17. doi:10.1530/ERC-17-0120.
   PubMed Web of Science ®Google Scholar
• Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M, et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer. 2013;49(6):1273–1279. doi:10.1016/j.ejca.2012.11.035.
   PubMed Web of Science ®Google Scholar
• Erlandsson A, Carlsson J, Lundholm M, Falt A, Andersson SO, Andren O, Davidsson S. M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate. 2019;79(4):363–369. doi:10.1002/pros.23742.
   PubMed Web of Science ®Google Scholar
• Kalsbeek AM, Chan EF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes A-M, Horvath LG, Kench JG, et al. Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. Aging. 2016;8(11):2702–2712. doi:10.18632/aging.101044.
   PubMedGoogle Scholar
• Xu X, Shao N, Qiao D, Wang Z, Song N, Song N. Expression of vascular endothelial growth factor and basic fibroblast growth factor in extramammary Paget disease. Int J Clin Exp Pathol. 2015;8:3062–3068.
   PubMed Web of Science ®Google Scholar
• Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mab is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–1743. e13. doi:10.1016/j.cell.2018.10.014.
   PubMed Web of Science ®Google Scholar
• Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D, Xu J, et al. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2018;24(13):3069–3078. doi:10.1158/1078-0432.CCR-17-2687.
   PubMed Web of Science ®Google Scholar